ANI Pharmaceuticals, Inc. (ANIP) Given Average Rating of “Buy” by Brokerages
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) has been given an average recommendation of “Buy” by the seven research firms that are covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $68.00.
Several analysts have recently weighed in on ANIP shares. ValuEngine upgraded ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. Canaccord Genuity started coverage on ANI Pharmaceuticals in a report on Monday, July 31st. They issued a “buy” rating and a $60.00 price objective for the company. Finally, BidaskClub upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 18th.
Institutional investors have recently made changes to their positions in the company. BNP Paribas Arbitrage SA lifted its holdings in shares of ANI Pharmaceuticals by 44.6% in the second quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock valued at $101,000 after buying an additional 664 shares during the period. Oppenheimer Asset Management Inc. acquired a new stake in shares of ANI Pharmaceuticals in the first quarter valued at $204,000. Municipal Employees Retirement System of Michigan lifted its holdings in shares of ANI Pharmaceuticals by 132.0% in the second quarter. Municipal Employees Retirement System of Michigan now owns 4,200 shares of the specialty pharmaceutical company’s stock valued at $197,000 after buying an additional 2,390 shares during the period. Crossmark Global Holdings Inc. acquired a new stake in shares of ANI Pharmaceuticals in the third quarter valued at $226,000. Finally, Stevens Capital Management LP acquired a new stake in shares of ANI Pharmaceuticals in the second quarter valued at $207,000. Institutional investors and hedge funds own 55.96% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “ANI Pharmaceuticals, Inc. (ANIP) Given Average Rating of “Buy” by Brokerages” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/11/05/ani-pharmaceuticals-inc-anip-given-average-rating-of-buy-by-brokerages.html.
ANI Pharmaceuticals (NASDAQ ANIP) opened at $61.97 on Friday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 2.49 and a current ratio of 3.45. ANI Pharmaceuticals has a 12-month low of $42.23 and a 12-month high of $65.81. The stock has a market capitalization of $721.83, a price-to-earnings ratio of 18.50 and a beta of 2.85.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.99 by $0.12. ANI Pharmaceuticals had a return on equity of 22.40% and a net margin of 4.45%. The company had revenue of $48.16 million during the quarter, compared to analyst estimates of $48.12 million. During the same quarter in the previous year, the firm posted $1.09 EPS. The firm’s quarterly revenue was up 25.0% on a year-over-year basis. sell-side analysts expect that ANI Pharmaceuticals will post 3.52 earnings per share for the current fiscal year.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.